In the late 1980s, medical supply companies sought to leverage their relationships with new customers by creating a broad portfolio of diverse products. Smith & Nephew is pursuing a different tack--having spent a decade making one acquisition after another, it spent the last several years selling off most of those businesses. What remains is a company focused on products that repair tissue, in areas such as orthopedics, wound care, and endoscopy.
by David Cassak
Having spent much of the 1980s acquiring a wide array of product lines, mostly in the US—every thing from orthopedic implants to operating room tables, intraocular lenses to casting materials—senior...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
